Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
Provided By GlobeNewswire
Last update: May 15, 2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients
Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates
Read more at globenewswire.com
